![Guillermo Villacampa: Marleen Kok presents the ESMO Breast 24 key message in translation research](https://oncodaily.com/pub/uploads/2024/05/GNyIr9lWAAAj0cM.png)
Guillermo Villacampa: Marleen Kok presents the ESMO Breast 24 key message in translation research
Paolo Tarantino shared the following post by Guillermo Villacampa, Biostatistician in the Oncology Data Science Group (OdysSey) at Vall d’Hebron Institute of Oncology (VHIO), adding:
“Outstanding presentation by Marleen Kok!”
Quoting Guillermo Villacampa’s post:
“Marleen Kok presents the ESMO Breast 24 key message in translation research. Excellent presentation! And thank you for the mention of the new HER2DX data.”
Source: Paolo Tarantino/X and Guillermo Villacampa/X
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.